Owkin’s Agentic AI Will Support Biomed Research While Preserving Data Sovereignty
The nation of Estonia, renowned for its advanced digital infrastructure, has embarked on a pioneering partnership with Owkin, a company specializing in agentic artificial intelligence. This collaboration focuses on leveraging “sovereign AI” to enhance biomedical research and various scientific inquiries while ensuring the preservation of data sovereignty.
Estonia, with a population of approximately 1.36 million, is recognized globally for its sophisticated digital public services. This includes a wide array of healthcare applications such as electronic medical records, e-prescriptions, e-consultations, e-ambulance services, and a comprehensive nationwide picture archiving and communication system, all according to the World Health Organization (WHO).
This strategic partnership was formally announced by Metrosert, Estonia’s state-owned technical and scientific research organization. The institution’s role resembles that of the National Institute of Standards and Technology in the United States, overseeing the evaluation of Owkin’s AI platform K Pro. The partnership aims to investigate how this technology can assist researchers in handling intricate health data safely within a well-regarded national infrastructure.
The primary goal behind this collaboration is to facilitate “reproducible analysis and a more rapid generation of scientific insight,” all while maintaining stringent data sovereignty principles, according to Owkin. The cohesiveness and effectiveness of Estonia’s health system is underpinned by its Ministry of Social Affairs, which is responsible for health policy creation, strategic foresight, and regulatory oversight.
Under Estonia’s social health insurance model, the Estonian Health Insurance Fund manages public finances and establishes contracts with healthcare providers to deliver services to about 94% of the population. Minister of Economic Affairs, Liina Vahtras, highlighted the years Estonia has dedicated to building trustworthy digital infrastructures and health-data capabilities, stating, “The next step is enabling those assets to create greater value for science and future health innovation.” This collaboration with Owkin enables Estonia to further its status as a forerunner in the secure utilization of health data.
The initiative will utilize AI to analyze the nation’s biomedical data, facilitating groundbreaking scientific discoveries, improved research capabilities, and enhanced patient outcomes. Areas such as oncology will be explored under the collaboration, connecting clinical, molecular, medical imaging, and treatment-outcome data.
Regarding the implementation of this “sovereign AI” within Estonia, Sepideh Shokrpour, Owkin’s Vice President of Global Ecosystem and External Affairs, noted that K Pro is specifically designed to function where data resides, within a secure Estonian research environment, ensuring that raw patient-level data remains protected. The operational framework governing external model connectivity and data access will comply with security and governance requirements agreed upon with Estonian authorities.
This deployment marks a significant milestone for Owkin, serving as a potential model for future partnerships aimed at applying AI in similar contexts across other nations. Shokrpour expressed optimism that Estonia could emerge as a reference model for countries looking to harness AI to derive scientific and economic value from national health data while adhering to principles of sovereignty and governance. This adaptable model will align with each country’s unique infrastructure, legal framework, and research objectives.
The immediate beneficiaries of this initiative will be approved Estonian researchers who will gain enhanced access to the intricate health data, thereby enabling them to generate reproducible evidence more efficiently. Shokrpour indicated that this strengthened research capability could bolster partnerships with Estonian universities, biotechnology firms, and life sciences entities, potentially attracting international research and development efforts. Ultimately, such advancements are expected to contribute to improved biomedical research outcomes and patient care.
It is essential to note that the first phase of this initiative focuses solely on research use and does not encompass clinical decision-making. Access to Estonian health data will be managed by relevant institutions, with proper permissions for research. The K Pro platform includes robust enterprise controls such as SSO/SAML, role-based access, and audit logging, with specific access parameters being established through collaboration between Metrosert and relevant Estonian authorities.
In the realm of private-sector innovation, Owkin is also engaging with various pharmaceutical and biomedical companies, including Sanofi, Boehringer Ingelheim, and Servier. Notable collaborations also extend to AstraZeneca, who is leveraging K Pro for expedited analysis and forecasting in drug trials.
Owkin, characterized as a “French-American” company with dual headquarters in Paris and New York, positions K Pro as an AI agent platform that autonomously organizes a spectrum of AI skills and tools aimed at helping scientists untangle complex biological questions and accelerate research progress.